regavirumab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Envelope glycoprotein BINHIBITOR
gB inhibitor
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107880 ↗
Also known as
- lyophilized regavirumab-human serum albumin-amino acetic acid
- mca-c23
- mca c23-hsa-glycine
- regavirumab
- ti-23
- ti-23
- ti-23 human monoclonal antibody